Literature DB >> 12132008

Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.

Ariel Pablos-Mendez1, Deepthiman K Gowda, Thomas R Frieden.   

Abstract

The emergence and spread of multidrug-resistant tuberculosis (MDR-TB), i.e. involving resistance to at least isoniazid and rifampicin, could threaten the control of TB globally. Controversy has emerged about the best way of confronting MDR-TB in settings with very limited resources. In 1999, the World Health Organization (WHO) created a working group on DOTS-Plus, an initiative exploring the programmatic feasibility and cost-effectiveness of treating MDR-TB in low-income and middle-income countries, in order to consider the management of MDR-TB under programme conditions. The challenges of implementation have proved more daunting than those of access to second-line drugs, the prices of which are dropping. Using data from the WHO/International Union Against Tuberculosis and Lung Disease surveillance project, we have grouped countries according to the proportion of TB patients completing treatment successfully and the level of MDR-TB among previously untreated patients. The resulting matrix provides a reasonable framework for deciding whether to use second-line drugs in a national programme. Countries in which the treatment success rate, i.e. the proportion of new patients who complete the scheduled treatment, irrespective of whether bacteriological cure is documented, is below 70% should give the highest priority to introducing or improving DOTS, the five-point TB control strategy recommended by WHO and the International Union Against Tuberculosis and Lung Disease. A poorly functioning programme can create MDR-TB much faster than it can be treated, even if unlimited resources are available. There is no single prescription for controlling MDR-TB but the various tools available should be applied wisely. Firstly, good DOTS and infection control; then appropriate use of second-line drug treatment. The interval between the two depends on the local context and resources. As funds are allocated to treat MDR-TB, human and financial resources should be increased to expand DOTS worldwide.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12132008      PMCID: PMC2567530     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  21 in total

1.  The treatment journey of a patient with multidrug-resistant tuberculosis in South Africa: is it patient-centred?

Authors:  M Loveday; N Padayatchi; A Voce; J Brust; K Wallengren
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

Review 2.  Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis.

Authors:  A Fraser; M Paul; A Attamna; L Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

3.  Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis.

Authors:  Kai Blöndal
Journal:  Bull World Health Organ       Date:  2007-05       Impact factor: 9.408

4.  Molecular modeling and dynamics studies of cytidylate kinase from Mycobacterium tuberculosis H37Rv.

Authors:  Rafael Andrade Caceres; Luís Fernando Saraiva Macedo Timmers; Ana Luiza Vivan; Cristopher Zandoná Schneider; Luiz Augusto Basso; Walter Filgueira De Azevedo; Diogenes Santiago Santos
Journal:  J Mol Model       Date:  2008-03-15       Impact factor: 1.810

5.  The domain architecture of PtkA, the first tyrosine kinase from Mycobacterium tuberculosis, differs from the conventional kinase architecture.

Authors:  Anna Niesteruk; Hendrik R A Jonker; Christian Richter; Verena Linhard; Sridhar Sreeramulu; Harald Schwalbe
Journal:  J Biol Chem       Date:  2018-06-08       Impact factor: 5.157

6.  Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.

Authors:  Anandi Martin; Juan Carlos Palomino; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

7.  Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Authors:  Anne J Lenaerts; Veronica Gruppo; Karen S Marietta; Christine M Johnson; Diane K Driscoll; Nicholas M Tompkins; Jerry D Rose; Robert C Reynolds; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  Tuberculosis among homeless population from Medellín, Colombia: associated mental disorders and socio-demographic characteristics.

Authors:  José Mauricio Hernández Sarmiento; Nidia Correa; Marta Correa; José Gabriel Franco; Matilde Alvarez; Clara Ramírez; Lina M Gómez; Antonio Carlos Toro; Nora Helena Londoño; Milton Martínez; Mary Alejandra Restrepo; Elsa Zapata; Gloria Isabel Mejía; Jaime Robledo
Journal:  J Immigr Minor Health       Date:  2013-08

9.  Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method.

Authors:  Anandi Martin; Mirtha Camacho; Françoise Portaels; Juan Carlos Palomino
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

10.  An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins.

Authors:  Rahul Sharma; Vikrant Singh Rajput; Salma Jamal; Abhinav Grover; Sonam Grover
Journal:  Sci Rep       Date:  2021-07-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.